Overview

Evaluate Efficacy, and Safety of Topical Therapy and Etanercept in Subjects With Moderate to Severe Plaque Psoriasis

Status:
Completed
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
The primary hypothesis of this trial is that the addition of short courses of clobetasol propionate foam to etanercept monotherapy in subjects with moderate to severe plaque psoriasis will yield greater efficacy compared with etanercept monotherapy, as measured by PASI 75 at Week 12.
Phase:
Phase 3
Details
Lead Sponsor:
Amgen
Collaborator:
Wyeth is now a wholly owned subsidiary of Pfizer
Treatments:
Clobetasol
Etanercept